CSIMarket Company Name, Ticker, Competitors, else..
 
Aptevo Therapeutics Inc   (NASDAQ: APVO)
Other Ticker:  
 
 
Price: $2.5700 $0.10 4.053%
Day's High: $2.6329 Week Perf: -2.65 %
Day's Low: $ 2.49 30 Day Perf: -24.63 %
Volume (M): 37 52 Wk High: $ 134.94
Volume (M$): $ 94 52 Wk Avg: $13.73
Open: $2.58 52 Wk Low: $2.35



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 0
 Employees 34
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Aptevo Therapeutics Inc
Aptevo Therapeutics Inc is a biotechnology company that focuses on the development and commercialization of novel therapeutics for the treatment of various diseases. The company is involved in the discovery and development of innovative antibody-based therapeutics, as well as in the manufacturing and commercialization of biologics for the treatment of cancer and autoimmune diseases. Aptevo Therapeutics Inc is committed to advancing breakthrough treatments and improving patients' lives.


   Company Address: 2401 4th Avenue Seattle 98121 WA
   Company Phone Number: 838-0500   Stock Exchange / Ticker: NASDAQ APVO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        1.8% 
JNJ        0.49% 
LLY        1.55% 
MRK   -1.77%    
SNY   -3.43%    
TEVA   -3.65%    
• View Complete Report
   



Aptevo Therapeutics Inc

APVO's Game-Changing Performance Emerges in the Major Pharmaceutical Preparations Market during Latest Fiscal Period

Financial News Report: Aptevo Therapeutics Inc's Operating Shortfall and Share Performance
Aptevo Therapeutics Inc, a smaller corporation in the Major Pharmaceutical Preparations industry, recently announced its financial results for the third quarter of 2023. The company reported an operating shortfall of $-6.561 million, which indicates a decrease compared to the same period the previous year. Despite operating primarily in the expansion span, this result has overshadowed the company's performance in the comparable period.
However, there is some positive news regarding the losses as they have been trimmed from the previous year. In the third quarter of 2022, the company reported a loss of $-7.644 million, while in the most recent fiscal period, the loss stood at $-6.334 million. This reduction in losses signifies a significant achievement for Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc

Aptevo Therapeutics Inc Reports Operating Deficit of $-8.178 Million, Prompting Concerns About Company's Financial Health


Introduction
Aptevo Therapeutics Inc, a pharmaceutical company, recently released its financial results for the period from April to June 2023. While shareholders did not foresee any adjustments at the company's top-line, they expressed concerns about the operating deficit of $-8.178 million during that period. To gain a better understanding of the current situation, it is helpful to analyze the company's performance in the previous year.
Previous Performance
In the second quarter of 2022, Aptevo Therapeutics Inc reported an operating deficit of $-7.562 million. This context allows us to assess the progress the company has made, as well as the challenges it faces in their evolving business model.
Challenges and Concerns
The most significant concern regarding Aptevo Therapeutics Inc's financial results is the net deficit of $28.010 million in the most recent fiscal period. This deficit raises questions about the company's ability to establish a viable business model. Shareholders and investors closely monitor these figures as they indicate the financial health and sustainability of the company.
Future Outlook
Looking ahead, Aptevo Therapeutics Inc is expected to report its next financial earnings on November 09, 2023. This upcoming financial report is highly anticipated by shareholders and investors, as they seek insights into the company's progress in addressing its operating deficit.
Share Performance
In context with the financial results, it is important to note that over the past week, Aptevo Therapeutics Inc shares experienced a drop of -1.89%. This decline has further impacted the year-to-date performance, which stands at -54.59%. However, it is worth mentioning that the shares are still trading 36.8% above their 52-week low. This indicates some level of resilience amidst market volatility.
Aptevo Therapeutics Inc

Aptevo Therapeutics Inc Surpasses Expectations in the First Quarter of 2023, Setting a Promising Trend for Shareholders

Investors, rejoice! The stock market has reason to celebrate with great news from the recent earnings season. The first quarter of 2023 earnings season proved to be a turning point for many companies, including the Major Pharmaceutical Preparations company.Our attention, however, turns to Aptevo Therapeutics Inc - a company that we are eagerly anticipating their next financial earnings report on August 10, 2023.
In the first quarter of 2023 earnings season, Aptevo Therapeutics Inc reported an impressive EPS of $0.39 per share, a significant turnaround from a year ago when they reported a loss of $-1.55 per share. The company also revealed positive net profits per share, having moved from a negative value of $-0.84 per share that was reported in the previous quarter. The revenue performance for the quarter wasn't left behind either, remaining unscathed at $0.00 million, a result that was comparable to what the firm achieved the previous year. Such news provides investors with confidence that Aptevo Therapeutics Inc's performance in the upcoming fiscal period could be even betterPerhaps the highlight of these reports is that the Major Pharmaceutical Preparations company recorded net income of $2.773 million, a remarkable improvement against a loss of $-7.697 million in the previous year's reports. With such a remarkable recovery, investors can't wait to see what the future holds for this firm.
Looking at the overall trend in the stock market, it is exciting to see companies like Aptevo Therapeutics Inc. and the Major Pharmaceutical Preparations company turn their fortunes around, and in so doing, provide great news for their shareholders. The first quarter of 2023 has set a tone that we hope will continue throughout the rest of the year and beyond. As investors, we can?t wait to see what the future holds!









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com